Mirum Pharmaceuticals, Inc. today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November ...

Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental ...

Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Psoriasis is an autoimmune disorder that causes pruritus. This condition occurs when your immune system overreacts, causing rapid skin cell turnover which leads to swollen and itchy patches. It's ...

Nippon Chemiphar Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of cough, pain, pruritus, substance abuse and dependence, and ...

Secondary outcomes of interest included the prevalence of and costs of comorbid conditions, including depression, anxiety, substance use disorder, sleep-related breathing disorders, central disorders ...

Complexposttraumatic stress disorder (c-PTSD or CPTSD) is a mental health condition that can happen after repeated or prolonged trauma. If you have CPTSD, you might have trouble feeling safe.

Pemphigoid gestationis is a rare, autoimmune, vesiculo-bullous, intensely pruritic disorder, which develops more frequently in late pregnancy or in the postpartum period. Previously this condition ...

Body dysmorphia, also called body dysmorphic disorder (BDD), is a mental health disorder that leads to extreme distress over your appearance. You may think certain parts of your body are defects.

Conduct disorder is a type of mental illness diagnosed in children where they demonstrate persistent or repeated violent, threatening, or intimidating behavior that goes outside of social norms. This ...

a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme ...

In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and ...